1. Home
  2. NCMI vs IMRX Comparison

NCMI vs IMRX Comparison

Compare NCMI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.80

Market Cap

306.0M

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$4.71

Market Cap

265.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
IMRX
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
265.3M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
NCMI
IMRX
Price
$3.80
$4.71
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$5.63
$17.20
AVG Volume (30 Days)
449.1K
1.4M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
37.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.20
N/A
Revenue Next Year
$6.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$2.90
52 Week High
$5.14
$10.08

Technical Indicators

Market Signals
Indicator
NCMI
IMRX
Relative Strength Index (RSI) 51.47 44.45
Support Level $3.35 $4.49
Resistance Level $4.03 $5.36
Average True Range (ATR) 0.16 0.29
MACD -0.01 -0.03
Stochastic Oscillator 23.68 6.48

Price Performance

Historical Comparison
NCMI
IMRX

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: